Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 1
1986 2
1987 2
1988 1
1994 1
1999 1
2004 2
2006 8
2007 8
2008 6
2009 7
2010 10
2011 13
2012 6
2013 7
2014 6
2015 15
2016 15
2017 10
2018 16
2019 12
2020 9
2021 11
2022 6
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

167 results

Results by year

Filters applied: . Clear all
Page 1
HIV in Iran: onset, responses, and future directions.
SeyedAlinaghi S, Taj L, Mazaheri-Tehrani E, Ahsani-Nasab S, Abedinzadeh N, McFarland W, Mohraz M, Mirzazadeh A. SeyedAlinaghi S, et al. Among authors: mohraz m. AIDS. 2021 Mar 15;35(4):529-542. doi: 10.1097/QAD.0000000000002757. AIDS. 2021. PMID: 33252485 Free PMC article. Review.
Effect of 8 Weeks of Hospital-Based Resistance Training Program on TCD4+ Cell Count and Anthropometric Characteristic of Patients With HIV in Tehran, Iran: A Randomized Controlled Trial.
Ghayomzadeh M, SeyedAlinaghi S, Shamsi MM, Rezaei S, Earnest CP, Akbarnejad S, Taj L, Mohraz M, Navalta JW, Ghasemi P, Voltarelli FA. Ghayomzadeh M, et al. Among authors: mohraz m. J Strength Cond Res. 2019 Apr;33(4):1146-1155. doi: 10.1519/JSC.0000000000002394. J Strength Cond Res. 2019. PMID: 29219895 Clinical Trial.
Efficacy and safety of an inactivated virus-particle vaccine for SARS-CoV-2, BIV1-CovIran: randomised, placebo controlled, double blind, multicentre, phase 3 clinical trial.
Mohraz M, Vahdat K, Ghamari SH, Abbasi-Kangevari M, Ghasemi E, Ghabdian Y, Rezaei N, Pouya MA, Abdoli A, Malekpour MR, Koohgir K, Saeedi Moghaddam S, Tabarsi P, Moghadami M, Khorvash F, Khodashahi R, Salehi M, Hosseini H. Mohraz M, et al. BMJ. 2023 Sep 21;382:e070464. doi: 10.1136/bmj-2023-070464. BMJ. 2023. PMID: 37734752 Free PMC article. Clinical Trial.
Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline.
Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, Mohraz M, Mardani M, Fattahi MR, Poustchi H, Nikbin M, Nabavi M, Adibi P, Ziaee M, Behnava B, Rezaee-Zavareh MS, Colombo M, Massoumi H, Bizri AR, Eghtesad B, Amiri M, Namvar A, Hesamizadeh K, Malekzadeh R. Alavian SM, et al. Among authors: mohraz m. Hepat Mon. 2016 Aug 13;16(8):e40959. doi: 10.5812/hepatmon.guideline. eCollection 2016 Aug. Hepat Mon. 2016. PMID: 27799966 Free PMC article. Review.
Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency.
Delavari S, Abolhassani H, Abolnezhadian F, Babaha F, Iranparast S, Ahanchian H, Moazzen N, Nabavi M, Arshi S, Fallahpour M, Bemanian MH, Shokri S, Momen T, Sadeghi-Shabestari M, Molatefi R, Shirkani A, Vosughimotlagh A, Safarirad M, Sharifzadeh M, Pashangzadeh S, Salami F, Shirmast P, Rezaei A, Moeini Shad T, Mohraz M, Rezaei N, Hammarström L, Yazdani R, Aghamohamamdi A. Delavari S, et al. Among authors: mohraz m. J Clin Immunol. 2021 Feb;41(2):345-355. doi: 10.1007/s10875-020-00928-x. Epub 2020 Dec 1. J Clin Immunol. 2021. PMID: 33263173 Free PMC article.
HIV drug resistance among naïve HIV-infected patients in Iran.
Farrokhi M, Gholami M, Mohraz M, McFarland W, Baesi K, Abbasian L. Farrokhi M, et al. Among authors: mohraz m. J Res Med Sci. 2019 Apr 26;24:31. doi: 10.4103/jrms.JRMS_689_18. eCollection 2019. J Res Med Sci. 2019. PMID: 31143232 Free PMC article.
167 results